Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study

Akhtar et al., The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634, Sep 2022

Source

PDF

All
Studies

Meta
Analysis

https://c19ivm.org/akhtar.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,700+ studies for 169 treatments. c19ivm.org

Retrospective 423 patients in Pakistan, 216 receiving 6 day treatment, showing lower mortality, lower ICU admission, and faster viral clearance with treatment. Limited baseline information per group is provided. There were more severe patients in the ivermectin group. Logistic regression results are mentioned without full details. The difference in mortality was not statistically significant in logistic regression.

This study is excluded in meta analysis: pending additional information from authors.

Important missing comments or errors? Let us know.

risk of death, 90.4% lower, RR 0.10, p < 0.001, treatment 2 of 216 (0.9%), control 20 of 207 (9.7%), NNT 11.

risk of ICU admission, 71.6% lower, RR 0.28, p < 0.001, treatment 8 of 216 (3.7%), control 27 of 207 (13.0%), NNT 11.

risk of no hospital discharge, 79.6% lower, RR 0.20, p < 0.001, treatment 10 of 216 (4.6%), control 47 of 207 (22.7%), NNT 5.5.

time to viral-, 58.8% lower, relative time 0.41, p < 0.001, treatment mean 8.39 (±2.04) n=216, control mean 20.38 (±6.32) n=207.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Akhtar et al., 1 Sep 2022, retrospective, Pakistan, peer-reviewed, mean age 51.9, 9 authors, dosage 12mg days 1-6. Contact: umarraza028@gmail.com.

This Paper Ivermectin All

Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study.

Tehseen Akhtar, Amber Hanif, Pyar Ali, Muhammad Hussain Haroon, Nimra Akram, Muhammad Umar Raza, Khalid Imran, Nimra Shakeel, Ramsha Shakeel

The Professional Medical Journal, doi:10.29309/tpmj/2022.29.09.6634

Material & Methods: Medical records of 423 patients during a selected duration of 6 months were reviewed. Patients were stratified into two groups based on whether or not they received a 6-day course of ivermectin in addition to the standard treatment for COVID-19. Primary outcome measures were rate of mortality, days from the start of treatment to negative SARS-CoV-2 PCR, and rate of step-up to the intensive care unit. Results: Patients who received ivermectin required a lesser number of days (8.39 days ± 2.04) to become COVID negative than the patients who didn't receive ivermectin (20.38 days ± 6.32), (p < 0.001). Multinomial logistic regression showed that the patients who were given ivermectin for COVID 19 infection were four times more likely to be discharged home than stepping up to ICU. The ICU step-up rate in the ivermectin group was found to be 3.7% compared to 13.04% in the non-ivermectin group. No significant differences in mortality were found. Conclusion: Treatment with ivermectin in COVID-19 infection is associated with improved outcomes in terms of reduction in duration of illness as well as the progression of disease severity.

References

Adejumo, Impact of COVID-19 pandemic on renal care services in Nigeria, Pan Afr Med J, doi:10.11604/pamj.supp.2020.35.24403

Behera, Patro, Singh, Chandanshive, Kumar et al., Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study, doi:10.1101/2020.10.29.20222661

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1042/bj20120150

Chen, Klein, Garibaldi, Li, Wu et al., Aging in COVID-19: Vulnerability, immunity and intervention, Ageing Res Rev, doi:10.1016/j.arr.2020.101205

Clinic, None, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.04.010

Cohen, Hall, John, Rapoport, The Early Natural History of SARS-CoV-2 Infection: Clinical Observations from an Urban, Ambulatory COVID

Dr, Ruth, Pfau, Hospital, None

Inciardi, Adamo, Lupi, Cani, Pasquale et al., Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, doi:10.1093/eurheartj/ehaa388

Kumanan, Rajasooriyar, Guruparan, Sreeharan, The Impact of COVID-19 on the Delivery of Critical Health Care: Experience from a Non-High-Income Country, Asia Pac J Public Health, doi:10.1177/1010539520963626

Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol, doi:10.1016/j.vetpar.2004.11.028

Lippi, Wong, Henry, Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis, Pol Arch Intern Med, doi:10.20452/pamw.15272

Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res, doi:10.1016/j.antiviral.2018.09.010

Mbbs, Dr, None

Mbbs, Medical Officer, Ruth, Pfau, Hospital, None

Mbbs, Officer, Ruth, Pfau, Hospital, None

Muniyappa, Gubbi, COVID-19 pandemic, coronaviruses, and diabetes mellitus, Am J Physiol Endocrinol Metab, doi:10.1152/ajpendo.00124.2020

Patt, Gordan, Diaz, Okon, Grady et al., Impact of COVID-19 on Cancer Care: How the pandemic is delaying cancer diagnosis and treatment for American seniors, JCO Clin Cancer Inform, doi:10.1200/cci.20.00134

Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID Nineteen Study, Chest, doi:10.1016/j.chest.2020.10.009

Santos, Natural history of COVID-19 and current knowledge on treatment therapeutic options, Biomed Pharmacother, doi:10.1016/j.biopha.2020.110493

Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/bj20120150

Wang, Lv, Wang, Qiu, Yang, Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res, doi:10.1016/j.virusres.2019.01.010

DOI record: { "DOI": "10.29309/tpmj/2022.29.09.6634", "ISSN": [ "2071-7733", "1024-8919" ], "URL": "http://dx.doi.org/10.29309/TPMJ/2022.29.09.6634", "abstract": "Objective: To investigate the efficacy of ivermectin in the treatment of mild, moderate, and severe COVID-19 infection. Study Design: Retrospective Cohort study. Setting: COVID-19 Treatment Centre, Dr. Ruth K M Pfau Civil Hospital Karachi. Period: July 2020 to December 2020. Material & Methods: Medical records of 423 patients during a selected duration of 6 months were reviewed. Patients were stratified into two groups based on whether or not they received a 6-day course of ivermectin in addition to the standard treatment for COVID-19. Primary outcome measures were rate of mortality, days from the start of treatment to negative SARS-CoV-2 PCR, and rate of step-up to the intensive care unit. Results: Patients who received ivermectin required a lesser number of days (8.39 days ± 2.04) to become COVID negative than the patients who didn't receive ivermectin (20.38 days ± 6.32), (p < 0.001). Multinomial logistic regression showed that the patients who were given ivermectin for COVID 19 infection were four times more likely to be discharged home than stepping up to ICU. The ICU step-up rate in the ivermectin group was found to be 3.7% compared to 13.04% in the non-ivermectin group. No significant differences in mortality were found. Conclusion: Treatment with ivermectin in COVID-19 infection is associated with improved outcomes in terms of reduction in duration of illness as well as the progression of disease severity.", "author": [ { "affiliation": [], "family": "Tehseen Akhtar", "sequence": "first" }, { "affiliation": [], "family": "Amber Hanif", "sequence": "additional" }, { "affiliation": [], "family": "Pyar Ali", "sequence": "additional" }, { "affiliation": [], "family": "Muhammad Hussain Haroon", "sequence": "additional" }, { "affiliation": [], "family": "Nimra Akram", "sequence": "additional" }, { "affiliation": [], "family": "Muhammad Umar Raza", "sequence": "additional" }, { "affiliation": [], "family": "Khalid Imran", "sequence": "additional" }, { "affiliation": [], "family": "Nimra Shakeel", "sequence": "additional" }, { "affiliation": [], "family": "Ramsha Shakeel", "sequence": "additional" } ], "container-title": "The Professional Medical Journal", "container-title-short": "TPMJ", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 9, 2 ] ], "date-time": "2022-09-02T18:24:46Z", "timestamp": 1662143086000 }, "deposited": { "date-parts": [ [ 2022, 9, 2 ] ], "date-time": "2022-09-02T18:24:46Z", "timestamp": 1662143086000 }, "indexed": { "date-parts": [ [ 2022, 9, 2 ] ], "date-time": "2022-09-02T18:42:42Z", "timestamp": 1662144162310 }, "is-referenced-by-count": 0, "issue": "09", "issued": { "date-parts": [ [ 2022, 9, 1 ] ] }, "journal-issue": { "issue": "09", "published-online": { "date-parts": [ [ 2022, 9, 1 ] ] } }, "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 9, 1 ] ], "date-time": "2022-09-01T00:00:00Z", "timestamp": 1661990400000 } } ], "link": [ { "URL": "http://theprofesional.com/index.php/tpmj/article/download/6634/4970", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://theprofesional.com/index.php/tpmj/article/download/6634/4970", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "11864", "original-title": [], "page": "1384-1391", "prefix": "10.29309", "published": { "date-parts": [ [ 2022, 9, 1 ] ] }, "published-online": { "date-parts": [ [ 2022, 9, 1 ] ] }, "publisher": "Independent Medical Trust", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://theprofesional.com/index.php/tpmj/article/view/6634" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pulmonary and Respiratory Medicine", "Pediatrics, Perinatology and Child Health" ], "subtitle": [], "title": "Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study.", "type": "journal-article", "volume": "29" }

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0